From reactive "sick-care" to proactive health care

Most actionable findings on a Prenuvo scan are not cancer, but early-stage chronic conditions — MASLD, cerebral small vessel disease, asymptomatic aneurysms, fibroids, disc degeneration, and body composition pathologies. These have meaningful prevalence and impact on healthspan, lifespan, and lifetime cost when caught early. Framing whole-body MRI purely as a cancer screen understates its clinical value.
‍
How the cascade is calibrated: pre-test probability applies cleanly to single-disease tests, less so to multi-condition tools like whole-body MRI. Prenuvo manages findings through staged triage: benign findings are resolved in-scan; low-risk findings are monitored; moderate-to-high-risk findings proceed to contrast imaging or referral; only persistently indeterminate cases move to biopsy.
‍
POLARIS data shows an effective positive biopsy rate of ~50% (vs ~25% for mammography in women 40–49) and a negative predictive value of 99.8%, indicating a low likelihood of missed cancer. Together, these reflect a well-calibrated screening approach.

First, the baseline. About 30% of adults report persistent, low-grade anxiety about their health due to lack of information. The real comparator to proactive screening isn’t zero anxiety — it’s the ongoing worry of not knowing.
‍
Second, the moment of a finding. Early findings can create anxiety, and we address this with unhurried Results Reviews and clear, screening-context communication. The key trade-off is between short-term anxiety from an early, often treatable finding and the deeper anxiety that comes later when disease presents symptomatically. Over time, early detection reduces anxiety rather than amplifies it.
‍
Third, risk stratification as an anxiety tool. Most findings are resolved as benign in-scan. Indeterminate findings are stratified — low-risk cases are monitored, higher-risk cases have clear next steps. Patients leave with reassurance or a defined plan, not uncertainty. In aggregate, a well-structured proactive approach produces lower cumulative anxiety than reactive care.

We respect current society positions and the evidence standards they uphold — but “not recommended” today should not be confused with “recommended against.” These positions evolve with evidence. Mammography, PSA testing, and Pap smears each took decades to move from controversy to endorsement.
‍
Two questions follow. First, what about patients who could have benefited during those decades while evidence was still emerging? For many, guidance arrived too late. Second, given that definitive mortality data may not be available for decades lifetimes, how should decisions be made today?
‍
The answer is evidence-informed care: be clear about what is known, what is not, and support patients in making informed choices about their own bodies. That is the approach we take, while actively building the evidence base — with POLARIS published, HERCULES underway, and ongoing transparency around both findings and limitations.

Quite the opposite. Every Prenuvo patient is encouraged to share their report with their primary care physician, and our reports are structured in the format PCPs expect — ONCO-RADS, organ-specific rules like Bosniak and O-RADS, longitudinal comparison across visits.
‍
We support referring physicians directly with priority scheduling, account management, and direct radiologist access for clinical questions.
‍
In Canada, a referral is required to scan; in the US, patients without a current primary care relationship are cared for through our preventive-health team and encouraged to bring their report into a primary-care relationship.
The number of referring physicians we work with grows every month.